NCT02407509View on ClinicalTrials.gov

Phase I Trial of VS-6766 Alone and in Combination With Everolimus

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

June 17, 2013

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Solid TumoursMultiple MyelomaLung CancerOvarian Cancer
Interventions
DRUG

VS-6766

DRUG

Everolimus

Trial Locations (3)

SM2 5PT

Royal Marsden NHS Foundation Trust, Sutton

Unknown

Guy's and St Thomas' Hospital, London

Gynaecological Unit - Royal Marsden NHS Foundation Trust, London

Sponsors

Collaborators (1)

Chugai Pharmaceutical
All Listed Sponsors
collaborator

Institute of Cancer Research, United Kingdom

OTHER

collaborator

Chugai Pharmaceutical

INDUSTRY

collaborator

Verastem, Inc.

INDUSTRY

lead

Royal Marsden NHS Foundation Trust

OTHER